Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation

Table 5 Incremental cost-effectiveness of 10- valent pneumococcal conjugate vaccine in terms of averted DALYs during three years follow-up from inclusion in the study in the intervention group, vaccinated sub-group (Sep. 2011 – Aug. 2012) and control group (Sep. 2009 – Aug. 2010) at Butajira rural health program site

Health outcomes	Cost*	Incremental cost	Effectiveness	Incremental effectiveness	Incremental cost- effectiveness ratio (ICER)
					No discounting	Discounting 3%
DALYs
< 1 year of age
Intervention	36.7	30.2	0.08	−0.01	Dominated	Dominated
Vaccinated	36.2	29.7	0.11	−0.04	Dominated	Dominated
Control	6.5		0.07
> 1 year of age
Intervention	36.3	30.0	0.0001	0.14	219.4	227.9
Vaccinated	32.9	26.6	0.0001	0.13	194.2	273.9
Control	6.3		0.1338
> 2 years of age
Intervention	31.0	29.2	0.00005	0.103	283.7	318.6
Vaccinated	29.1	27.2	0.00003	0.1009	264.9	282.6
Control	1.86		0.103
Total follow-up period
Intervention	46.1	33.3	0.08	0.12	268.0	281.4
Vaccinated	42.2	29.3	0.11	0.10	304.7	342.0
Control	12.8		0.20

* N.B: the costs for averted DALYs and ALRI incidences are not the same due to the difference in considered costs. For DALYs, all costs in relation to all infections and vaccination were considered. In the case of ALRI, only costs related to ALRI and vaccination were considered

ISSN: 1471-2458